PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-42.34%
Both companies show declining cash positions (-42.34% vs TRVN's -200.00%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-42.34%
Both TRVN and the company show zero Cash + Short-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.91%
Other current assets growth < half of TRVN's -100.00%. David Dodd sees a leaner approach to short-term items.
-41.98%
≥ 1.5x TRVN's -3.85%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-100.00%
Similar yoy growth to TRVN's -100.00%. Walter Schloss sees parallel capital spending strategies. Check utilization rates.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Less than half of TRVN's -4071.58%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-100.00%
Below half of TRVN's -724.25%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-42.01%
Below half of TRVN's -100.00%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-48.73%
Less than half of TRVN's -100.00%. David Dodd sees a more disciplined AP approach or lower volume.
-46.67%
Less than half of TRVN's -100.00%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.33%
Less than half of TRVN's -100.00%. David Dodd sees fewer expansions in other current obligations.
-39.56%
Less than half of TRVN's -100.00%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39.56%
Less than half of TRVN's -100.00%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.24%
Below half TRVN's 100.00%. Michael Burry suspects major net losses or high dividends vs. competitor.
99.72%
Less than half of TRVN's -1728.99%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Similar yoy changes to TRVN's -100.00%. Walter Schloss finds parallel equity item fluctuations.
-51.92%
Below half TRVN's 3557.01%. Michael Burry sees potential underperformance in building shareholder capital.
-42.01%
0.5-0.75x TRVN's -83.25%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
-46.67%
Less than half of TRVN's -100.00%. David Dodd sees less overall debt expansion vs. competitor.
42.23%
Less than half of TRVN's 460.27%. David Dodd sees better deleveraging or stronger cash buildup than competitor.